Spherical Nucleic Acids Deliver a New Package for Oliognucleotide Therapeutics
SNAs Are a Hopeful First Step in Boosting the Utility of Oligonucleotides to Treat a Variety of Human Diseases
Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Licensing & Collaborations for Tamiflu Patent
Threat of Avian Flu Pandemic Has Countries & Pharma Firms Exploring Manufacturing Options
- If profits are the carrot, compulsory licensing is the stick in the unfolding drama to ensure adequate supplies of oseltamivir throughout the world in an attempt to mitigate an avian flu pandemic. In dire situations, you want to have march-in rights, says Vijay Samant, CEO of vaccine manufacturer Vical ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.